Professor Iain McNeish

Affiliate (School of Cancer Sciences)

email: Iain.Mcneish@glasgow.ac.uk

RI Cancer Sciences, Beatson Institute, Garscube Estate, Switchback Road, G61 1BD

ORCID iD https://orcid.org/0000-0002-9387-7586

Publications

List by: Type | Date

Jump to: 2023 | 2022 | 2021 | 2020 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 1996

Number of items: 87.

2023

Banerjee, S. et al. (2023) Efficacy and safety of weekly paclitaxel plus vistusertib vs paclitaxel alone in patients with platinum-resistant ovarian high-grade serous carcinoma: the OCTOPUS multicenter, phase 2, randomized clinical trial. JAMA Oncology, 9(5), pp. 675-682. (doi: 10.1001/jamaoncol.2022.7966) (PMID:36928279) (PMCID:PMC10020933)

2022

Ho, G.-Y. et al. (2022) Epithelial-to-mesenchymal transition supports ovarian carcinosarcoma tumorigenesis and confers sensitivity to microtubule-targeting with eribulin. Cancer Research, 82(23), pp. 4457-4473. (doi: 10.1158/0008-5472.can-21-4012) (PMID:36206301) (PMCID:PMC9716257)

Spiliopoulou, P. et al. (2022) Dual G9A/EZH2 inhibition stimulates anti-tumour immune response in ovarian high grade serous carcinoma. Molecular Cancer Therapeutics, 21(4), pp. 522-534. (doi: 10.1158/1535-7163.MCT-21-0743) (PMID:35131874)

2021

Moreno, V. et al. (2021) Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial. Journal for ImmunoTherapy of Cancer, 9(12), e003645. (doi: 10.1136/jitc-2021-003645) (PMID:34893524) (PMCID:PMC8666888)

Spiliopoulou, P., Hinsley, S. , Mcneish, I. A. , Roxburgh, P. and Glasspool, R. (2021) Metronomic oral cyclophosphamide in relapsed ovarian cancer. International Journal of Gynecological Cancer, 31, pp. 1037-1044. (doi: 10.1136/ijgc-2021-002467) (PMID:34016703)

Ewing, A. et al. (2021) Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma. Clinical Cancer Research, 27(11), pp. 3201-3214. (doi: 10.1158/1078-0432.CCR-20-4068) (PMID:33741650) (PMCID:PMC7610896)

Macintyre, G. et al. (2021) FrenchFISH: Poisson Models for Quantifying DNA Copy Number From Fluorescence In Situ Hybridization of Tissue Sections. JCO Clinical Cancer Informatics, 5, pp. 176-186. (doi: 10.1200/cci.20.00075) (PMID:33570999)

2020

Talhouk, A. et al. (2020) Development and validation of the gene-expression predictor of high-grade-serous ovarian carcinoma molecular subTYPE (PrOTYPE). Clinical Cancer Research, 26(20), (doi: 10.1158/1078-0432.CCR-20-0103) (PMID:32554541) (PMCID:PMC7572656)

Millstein, J. et al. (2020) Prognostic gene expression signature for high-grade serous ovarian cancer. Annals of Oncology, 31(9), pp. 1240-1250. (doi: 10.1016/j.annonc.2020.05.019) (PMID:32473302) (PMCID:PMC7484370)

Leung, E. Y.L. et al. (2020) NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer. Molecular Therapy - Oncolytics, 16, pp. 289-301. (doi: 10.1016/j.omto.2020.02.001) (PMID:32195317) (PMCID:PMC7068056)

Blagih, J. et al. (2020) Cancer-specific loss of p53 leads to a modulation of myeloid and T cell responses. Cell Reports, 30(2), 481-496.e6. (doi: 10.1016/j.celrep.2019.12.028) (PMID:31940491) (PMCID:31940491)

2018

Rust, K. et al. (2018) Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience. BJOG: An International Journal of Obstetrics and Gynaecology, 125(11), pp. 1451-1458. (doi: 10.1111/1471-0528.15171) (PMID:29460478)

McGivern, N., El-Helali, A., Mullan, P., Mcneish, I. A. , Paul Harkin, D., Kennedy, R. D. and McCabe, N. (2018) Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer. Oncotarget, 9(4), pp. 4722-4736. (doi: 10.18632/oncotarget.23524) (PMID:29435137) (PMCID:PMC5797008)

Sierra Gonzalez, P. et al. (2018) Mannose impairs tumour growth and enhances chemotherapy. Nature, 563, pp. 719-723. (doi: 10.1038/s41586-018-0729-3) (PMID:30464341)

2017

Walton, J. B. et al. (2017) CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Scientific Reports, 7, 16827. (doi: 10.1038/s41598-017-17119-1) (PMID:29203787) (PMCID:PMC5715106)

Cooke, S. L. et al. (2017) The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma. Clinical Cancer Research, 23(24), pp. 7633-7640. (doi: 10.1158/1078-0432.CCR-17-1789) (PMID:28954785)

Oza, A. M. et al. (2017) Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2. Gynecologic Oncology, 147(2), pp. 267-275. (doi: 10.1016/j.ygyno.2017.08.022) (PMID:28882436)

Coleman, R. L. et al. (2017) Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 390(10106), pp. 1949-1961. (doi: 10.1016/S0140-6736(17)32440-6) (PMID:28916367) (PMCID:PMC5901715)

De Munck, J., Binks, A., Mcneish, I. A. and Aerts, J. L. (2017) Oncolytic virus-induced cell death and immunity: a match made in heaven? Journal of Leukocyte Biology, 102(3), pp. 631-643. (doi: 10.1189/jlb.5RU0117-040R) (PMID:28720686)

Kondrashova, O. et al. (2017) Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discovery, 7(9), pp. 984-998. (doi: 10.1158/2159-8290.CD-17-0419) (PMID:28588062) (PMCID:PMC5612362)

Babic, A. et al. (2017) Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. Cancer Causes and Control, 28(5), pp. 459-468. (doi: 10.1007/s10552-016-0841-3) (PMID:28050675) (PMCID:PMC5593071)

Goranova, T. et al. (2017) Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium. British Journal of Cancer, 116, pp. 1294-1301. (doi: 10.1038/bjc.2017.86) (PMID:28359078) (PMCID:PMC5482731)

Phelan, C. M. et al. (2017) Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 49, pp. 680-691. (doi: 10.1038/ng.3826) (PMID:28346442)

Sucheston-Campbell, L. E. et al. (2017) No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival. Cancer Epidemiology, Biomarkers and Prevention, 26(3), pp. 420-424. (doi: 10.1158/1055-9965.EPI-16-0631) (PMID:27677730) (PMCID:PMC5500198)

Hernandez-Fernaud, J. R. et al. (2017) Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nature Communications, 8, 14206. (doi: 10.1038/ncomms14206) (PMID:28198360) (PMCID:PMC5316871)

Kar, S. P. et al. (2017) Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 116(4), pp. 524-535. (doi: 10.1038/bjc.2016.426) (PMID:28103614) (PMCID:PMC5318969)

Swisher, E. M. et al. (2017) Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncology, 18(1), pp. 75-87. (doi: 10.1016/S1470-2045(16)30559-9) (PMID:27908594)

Weigert, M. et al. (2017) RIPK3 promotes adenovirus type 5 activity. Cell Death and Disease, 8, 3206. (doi: 10.1038/s41419-017-0110-8) (PMID:29238045) (PMCID:PMC5870599)

2016

Southey, M. C. et al. (2016) PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 53(12), pp. 800-811. (doi: 10.1136/jmedgenet-2016-103839) (PMID:27595995) (PMCID:PMC5200636)

Walton, J. et al. (2016) CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high grade serous carcinoma. Cancer Research, 76(20), pp. 6118-6129. (doi: 10.1158/0008-5472.CAN-16-1272) (PMID:27530326) (PMCID:PMC5802386)

Lawrenson, K. et al. (2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nature Communications, 7, 12675. (doi: 10.1038/ncomms12675) (PMID:27601076) (PMCID:PMC5023955)

Kar, S. P. et al. (2016) Genome-wide meta-analyses of breast, ovarian, and prostate cancer association studies identify multiple new susceptibility loci shared by at least two cancer types. Cancer Discovery, 6(9), pp. 1052-1067. (doi: 10.1158/2159-8290.CD-15-1227) (PMID:27432226) (PMCID:PMC5010513)

McNeish, I. A. (2016) Prognostic pathways in early-stage ovarian cancer: can gene expression transcend histological subtype? Annals of Oncology, 27(8), pp. 1366-1368. (doi: 10.1093/annonc/mdw254) (PMID:27358384)

Böhm, S. et al. (2016) Neoadjuvant chemotherapy modulates the immune microenvironment in metastases of tubo-ovarian high-grade serous carcinoma. Clinical Cancer Research, 22(12), pp. 3025-3036. (doi: 10.1158/1078-0432.ccr-15-2657) (PMID:27306793)

Singh, N., Gilks, C. B., Hirschowitz, L., Kehoe, S., McNeish, I. A. , Miller, D., Naik, R., Wilkinson, N. and McCluggage, W. G. (2016) Primary site assignment in tubo-ovarian high-grade serous carcinoma: consensus statement on unifying practice worldwide. Gynecologic Oncology, 141(2), pp. 195-198. (doi: 10.1016/j.ygyno.2015.10.022) (PMID:26827965)

Piskorz, A.M. et al. (2016) Methanol-based fixation is superior to buffered formalin for next-generation sequencing of DNA from clinical cancer samples. Annals of Oncology, 27(3), pp. 532-539. (doi: 10.1093/annonc/mdv613) (PMID:26681675) (PMCID:PMC4769995)

Clarke, C. J. et al. (2016) The initiator methionine tRNA drives secretion of type II collagen from stromal fibroblasts to promote tumor growth and angiogenesis. Current Biology, 26(6), pp. 755-765. (doi: 10.1016/j.cub.2016.01.045) (PMID:26948875) (PMCID:PMC4819511)

Meeks, H. D. et al. (2016) BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers. Journal of the National Cancer Institute, 108(2), djv315. (doi: 10.1093/jnci/djv315) (PMID:26586665) (PMCID:PMC4907358)

Tookman, L. A., Browne, A. K., Connell, C. M., Bridge, G., Ingemarsdotter, C. K., Dowson, S., Shibata, A., Lockley, M., Martin, S. and Mcneish, I. A. (2016) RAD51 and BRCA2 enhance oncolytic adenovirus Type 5 activity in ovarian cancer. Molecular Cancer Research, 14(1), pp. 44-55. (doi: 10.1158/1541-7786.mcr-15-0188-t) (PMID:26452665)

Hampras, S. S. et al. (2016) Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 7(43), pp. 69097-69110. (doi: 10.18632/oncotarget.10215) (PMID:27533245)

2015

Johnatty, S. E. et al. (2015) Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 21(23), pp. 5264-5276. (doi: 10.1158/1078-0432.CCR-15-0632) (PMID:26152742) (PMCID:PMC4624261)

Crosbie, E.J., Edmondson, R.J., Mcneish, I.A. and Sasieni, P. (2015) Are rigid management protocols stifling innovation in cancer treatment? BJOG: An International Journal of Obstetrics and Gynaecology, 122(11), pp. 1432-1434. (doi: 10.1111/1471-0528.13449) (PMID:26032865)

Kar, S. P. et al. (2015) Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention, 24(10), pp. 1574-1584. (doi: 10.1158/1055-9965.epi-14-1270) (PMID:26209509)

Browne, A., Tookman, L.A., Ingemarsdotter, C.K., Bouwman, R.D., Pirlo, K., Wang, Y., Mcneish, I.A. and Lockley, M. (2015) Pharmacological inhibition of 3 integrin reduces the inflammatory toxicities caused by oncolytic adenovirus without compromising anticancer activity. Cancer Research, 75(14), pp. 2811-2821. (doi: 10.1158/0008-5472.can-14-3761) (PMID:25977332)

Ingemarsdotter, C. K. et al. (2015) Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. Molecular Oncology, 9(4), pp. 791-805. (doi: 10.1016/j.molonc.2014.12.007) (PMID:25560085)

Lee, A. W. et al. (2015) Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. Gynecologic Oncology, 136(3), pp. 542-548. (doi: 10.1016/j.ygyno.2014.12.017) (PMID:25528498)

Chornokur, G. et al. (2015) Common genetic variation in cellular transport genes and epithelial ovarian cancer (EOC) risk. PLoS ONE, 10(6), e0128106. (doi: 10.1371/journal.pone.0128106) (PMID:26091520) (PMCID:PMC4474865)

Kelemen, L.E. et al. (2015) Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 47(8), pp. 888-897. (doi: 10.1038/ng.3336) (PMID:26075790) (PMCID:PMC4520768)

Kuchenbaecker, K. B. et al. (2015) Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 47(2), pp. 164-171. (doi: 10.1038/ng.3185)

2014

Okamoto, A. et al. (2014) Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. International Journal of Gynecological Cancer, 24(9), S20-S25. (doi: 10.1097/IGC.0000000000000289)

Rockall, A. G. et al. (2014) Repeatability of quantitative FDG-PET/CT and contrast enhanced CT in recurrent ovarian carcinoma: test retest measurements for tumor FDG uptake, diameter and volume. Clinical Cancer Research, 20(10), pp. 2751-2760. (doi: 10.1158/1078-0432.CCR-13-2634)

Glasspool, R.M. et al. (2014) A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. British Journal of Cancer, 110(8), pp. 1923-1929. (doi: 10.1038/bjc.2014.116)

McNeish, I.A. et al. (2014) A randomised placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Annals of Oncology, 25(10), pp. 1988-1995. (doi: 10.1093/annonc/mdu363)

2013

Glasspool, R.M. and McNeish, I.A. (2013) Clear cell carcinoma of ovary and uterus. Current Oncology Reports, 15(6), pp. 566-572. (doi: 10.1007/s11912-013-0346-0)

Leinster, A. et al. (2013) Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer. FASEB Journal, 27(10), pp. 4244-4253. (doi: 10.1096/fj.13-230441)

Hall, M., Gourley, C., Mcneish, I. , Ledermann, J., Gore, M., Jayson, G., Perren, T., Rustin, G. and Kaye, S. (2013) Targeted anti-vascular therapies for ovarian cancer: current evidence. British Journal of Cancer, 108(2), pp. 250-258. (doi: 10.1038/bjc.2012.541)

Whilding, L., Archibald, K., Kulbe, H., Balkwill, F., Oberg, D. and Mcneish, I. (2013) Vaccinia virus induces programmed necrosis in ovarian cancer cells. Molecular Therapy, 21(11), pp. 2074-2086. (doi: 10.1038/mt.2013.195)

2012

Archibald, K.M. et al. (2012) Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium. Oncogene, 31(48), pp. 4987-4995. (doi: 10.1038/onc.2011.653)

Young, A.-M. et al. (2012) Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo. Molecular Therapy, 20(9), pp. 1676-1688. (doi: 10.1038/mt.2012.116)

Leinster, D.A. et al. (2012) The peritoneal tumour microenvironment of high-grade serous ovarian cancer. Journal of Pathology, 227(2), pp. 136-145. (doi: 10.1002/path.4002)

Saha, A. et al. (2012) Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery. International Journal of Gynecological Cancer, 22(4), pp. 566-72. (doi: 10.1097/IGC.0b013e318247727f)

Emeagi, P.U. et al. (2012) Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy. Cancer Research, 72(6), pp. 1342-1352. (doi: 10.1158/0008-5472.CAN-11-2400)

Coley, H.M., Hatzimichael, E., Blagden, S., Mcneish, I. , Thompson, A., Crook, T. and Syed, N. (2012) Polo like kinase 2 tumour suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer. Oncotarget, 3(1), pp. 78-83.

Stone, R.L. et al. (2012) Paraneoplastic thrombocytosis in ovarian cancer. New England Journal of Medicine, 366(7), pp. 610-618. (doi: 10.1056/NEJMoa1110352)

2011

Ateh, D.D. et al. (2011) The intracellular uptake of CD95 modified paclitaxel-loaded poly(lactic-co-glycolic acid) microparticles. Biomaterials, 32(33), pp. 8538-8547. (doi: 10.1016/j.biomaterials.2011.07.060)

Ledermann, J.A. et al. (2011) Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. Journal of Clinical Oncology, 29(28), pp. 3798-804. (doi: 10.1200/JCO.2010.33.5208)

Vaughan, S. et al. (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer, 11(10), pp. 719-725. (doi: 10.1038/nrc3144)

Coward, J. et al. (2011) Interleukin-6 as a therapeutic target in human ovarian cancer. Clinical Cancer Research, 17(18), pp. 6083-6096. (doi: 10.1158/1078-0432.CCR-11-0945)

Syed, N. et al. (2011) Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Research, 71(9), pp. 3317-3327. (doi: 10.1158/0008-5472.CAN-10-2048)

Ledermann, J.A. et al. (2011) Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. International Journal of Gynecological Cancer, 21(4), pp. 763-70. (doi: 10.1097/IGC.0b013e31821b2669)

Connell, C.M., Shibata, A., Tookman, L.A., Archibald, K.M., Flak, M.B., Pirlo, K.J., Lockley, M., Wheatley, S.P. and McNeish, I.A. (2011) Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells. Journal of Clinical Investigation, 121(4), pp. 1283-1297. (doi: 10.1172/JCI43976)

Salako, M.A., Kulbe, H., Ingemarsdotter, C.K., Pirlo, K.J., Williams, S.L., Lockley, M., Balkwill, F.R. and McNeish, I.A. (2011) Inhibition of the inflammatory cytokine TNF-α increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression. Molecular Therapy, 19(3), pp. 490-499. (doi: 10.1038/mt.2010.247)

2010

Trimble, E.L. et al. (2010) Current academic clinical trials in ovarian cancer: gynecologic cancer intergroup and US national cancer institute clinical trials planning meeting, May 2009. International Journal of Gynecological Cancer, 20(7), pp. 1290-1298. (doi: 10.1111/IGC.0b013e3181ee1c01)

Harrington, K.J. et al. (2010) Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck. Clinical Cancer Research, 16(15), pp. 4005-4015. (doi: 10.1158/1078-0432.CCR-10-0196)

Merron, A., Baril, P., Martin-Duque, P., de la Vieja, A., Tran, L., Briat, A., Harrington, K.J., Mcneish, I.A. and Vassaux, G. (2010) Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours. European Journal of Nuclear Medicine and Molecular Imaging, 37(7), pp. 1377-1385. (doi: 10.1007/s00259-009-1379-3)

Delage, B., Fennell, D.A., Nicholson, L., Mcneish, I. , Lemoine, N.R., Crook, T. and Szlosarek, P.W. (2010) Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. International Journal of Cancer, 126(12), pp. 2762-72. (doi: 10.1002/ijc.25202)

Coughlan, L., Alba, R., Parker, A.L., Bradshaw, A.C. , Mcneish, I.A. , Nicklin, S. and Baker, A. (2010) Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses, 2(10), pp. 2290-2355. (doi: 10.3390/v2102290) (PMID:21994621) (PMCID:PMC3185574)

Elmetwali, T., Searle, P.F., Mcneish, I. , Young, L.S. and Palmer, D.H. (2010) CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus. Molecular Cancer, 9(52), (doi: 10.1186/1476-4598-9-52)

Flak, M.B., Connell, C.M., Chelala, C., Archibald, K., Salako, M.A., Pirlo, K.J., Lockley, M., Wheatley, S.P., Balkwill, F.R. and Mcneish, I.A. (2010) p21 promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker. Molecular Cancer, 9(175), (doi: 10.1186/1476-4598-9-175)

Ingemarsdotter, C.K., Baird, S.K., Connell, C.M., Öberg, D., Halldén, G. and McNeish, I.A. (2010) Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene, 29(45), pp. 6051-6063. (doi: 10.1038/onc.2010.335)

2009

Warwick, J., Vardaki, E., Fattizzi, N., Mcneish, I. , Jeyarajah, A., Oram, D., Hassan, L., Covens, A., Duffy, S. and Reynolds, K. (2009) Defining the surgical management of suspected early-stage ovarian cancer by estimating patient numbers through alternative management strategies. BJOG: An International Journal of Obstetrics and Gynaecology, 116(9), pp. 1225-1241. (doi: 10.1111/j.1471-0528.2009.02213.x)

Coughlan, L., Vallath, S., Saha, A., Flak, M., Mcneish, I.A. , Vassaux, G., Marshall, J.F., Hart, I.R. and Thomas, G.J. (2009) In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery. Journal of Virology, 83(13), pp. 6416-28. (doi: 10.1128/JVI.00445-09)

Young, A.M. and Mcneish, I.A. (2009) Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time. Future Oncology, 5(3), pp. 339-357. (doi: 10.2217/fon.09.11)

2008

Hagemann, T., Lawrence, T., Mcneish, I. , Charles, K.A., Kulbe, H., Thompson, R.G., Robinson, S.C. and Balkwill, F.R. (2008) "Re-educating" tumor-associated macrophages by targeting NF-kappaB. Journal of Experimental Medicine, 205(6), pp. 1261-1268. (doi: 10.1084/jem.20080108)

Pomel, C., Barton, D.P.J., Mcneish, I. and Shepherd, J. (2008) A statement for extensive primary cytoreductive surgery in advanced ovarian cancer. BJOG: An International Journal of Obstetrics and Gynaecology, 115(7), pp. 808-810. (doi: 10.1111/j.1471-0528.2008.01692.x)

Connell, C.M., Wheatley, S.P. and McNeish, I.A. (2008) Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysis. Cancer Research, 68(19), pp. 7923-7931. (doi: 10.1158/0008-5472.CAN-08-0817)

1996

Muir, K.W. , McNeish, I. , Grosset, D.G. and Metcalfe, M. (1996) Visualization of cardiac emboli from mitral valve papillary fibroelastoma. Stroke, 27(6), pp. 1133-1134. (PMID:8650729)

This list was generated on Wed Jun 7 19:26:10 2023 BST.

Jump to: Articles